Davies J A
Int J Clin Pharmacol Res. 1985;5(5):303-7.
Aspirin, sulfinpyrazone and the combination of aspirin/dipyridamole, which inhibit some aspects of platelet function, have been evaluated in large-scale clinical trials in secondary prevention of myocardial infarction. The Persantine-Aspirin Reinfarction Study using dipyridamole, and Anturane Reinfarction Trial and Anturan Reinfarction Italian Study with sulphinpyrazone did not yield conclusive results. There have been five trials in which aspirin has been compared with a placebo. When the results were pooled, the outcome was consistent with a reduction during aspirin treatment of 5-10% in mortality and 20% in coronary event-rate. Whether this small benefit to an individual patient is worthwhile, and whether the effect of aspirin is influenced by coexistent beta-blocker treatment, is not clear.
阿司匹林、磺吡酮以及阿司匹林/双嘧达莫组合，这些药物可抑制血小板功能的某些方面，已在心肌梗死二级预防的大规模临床试验中进行了评估。使用双嘧达莫的潘生丁 - 阿司匹林再梗死研究，以及使用磺吡酮的安妥明再梗死试验和安妥明再梗死意大利研究均未得出确凿结果。有五项试验将阿司匹林与安慰剂进行了比较。汇总结果后，结果表明阿司匹林治疗期间死亡率降低5 - 10%，冠状动脉事件发生率降低20%。对于个体患者而言，这种微小益处是否值得，以及阿司匹林的效果是否受同时存在的β受体阻滞剂治疗影响，尚不清楚。
